Table 4.
Comparison of clinical factors between SKP2 Low and SKP2 High groups.
| SKP2 Low | SKP2 High | P | ||
|---|---|---|---|---|
| Age (y) | 64.23 ± 5.47 | 66.57 ± 5.33 | 0.0998 | |
| cT stage (n) | 0.0277 | * | ||
| 1 | 25 | 16 | ||
| 2 | 2 | 8 | ||
| 3 | 2 | 5 | ||
| GS (n) | 0.0138 | * | ||
| 6 | 13 | 6 | ||
| 7 | 14 | 13 | ||
| 8 | 1 | 6 | ||
| 9 | 2 | 5 | ||
| TST (ng/dL) | 5.38 ± 1.87 | 4.51 ± 1.74 | 0.0984 | |
| PSA (ng/mL) | 8.68 ± 4.78 | 12.06 ± 7.70 | 0.0458 | * |
| PSAD | 0.30 ± 0.19 | 0.43 ± 0.29 | 0.0360 | * |
Data are expressed as means ± standard deviation unless otherwise indicated. cT stage = clinical tumour stage, GS = Gleason score, TST = testosterone, PSA = prostate-specific antigen, PSAD = PSA density.
*Statistical significance (p < 0.05).